Adamas: FDA OKs 2nd indication for Gocovri in Parkinson's

- GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications -

- Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT -

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended release capsules, gaining a second indication for the product. GOCOVRI is now approved as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes, in addition to its indication for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

https://finance.yahoo.com/news/adamas-announces-fda-approval-second-190700002.html